| Literature DB >> 35403935 |
Arpana Parihar1, Ayushi Singhal1,2, Neeraj Kumar1,2, Raju Khan3,4, Mohd Akram Khan1, Avanish K Srivastava1,2.
Abstract
Delayed diagnosis of cancer using conventional diagnostic modalities needs to be addressed to reduce the mortality rate of cancer. Recently, 2D nanomaterial-enabled advanced biosensors have shown potential towards the early diagnosis of cancer. The high surface area, surface functional groups availability, and excellent electrical conductivity of MXene make it the 2D material of choice for the fabrication of advanced electrochemical biosensors for disease diagnostics. MXene-enabled electrochemical aptasensors have shown great promise for the detection of cancer biomarkers with a femtomolar limit of detection. Additionally, the stability, ease of synthesis, good reproducibility, and high specificity offered by MXene-enabled aptasensors hold promise to be the mainstream diagnostic approach. In this review, the design and fabrication of MXene-based electrochemical aptasensors for the detection of cancer biomarkers have been discussed. Besides, various synthetic processes and useful properties of MXenes which can be tuned and optimized easily and efficiently to fabricate sensitive biosensors have been elucidated. Further, futuristic sensing applications along with challenges will be deliberated herein.Entities:
Keywords: Aptamer; Cancer diagnostics; Electrochemical devices; MXene; POCT
Year: 2022 PMID: 35403935 PMCID: PMC8995416 DOI: 10.1007/s40820-022-00845-1
Source DB: PubMed Journal: Nanomicro Lett ISSN: 2150-5551
Fig. 1Graphical representation of a estimated number of incident cases and mortality worldwide, both sexes and all ages (last access date: 10.12.2021); b the literature published on aptamer and MXene in last decade; c number of literature published for oncological application of aptamer and MXene in last decade (last access date: 16.12.2021). d Applications of MXene and Aptamer
Fig. 2Timeline of MXene for the synthesis and its application in the biomedical field
Cancer biomarkers associated with different types of cancer for which aptamers have been designed and exploited
| S. no. | Cancer biomarker | Cancer type | Function and properties | Aptamer sequence | References |
|---|---|---|---|---|---|
| 1 | VEGF- Protein | Breast cancer | Promotes angiogenesis Prognosis | 5′-GGG CCG TTC GAA CAC GAG CAT GGT GGG TGG TGG CCC TAG GAT GAC CTG AGT ACT GTC C-3′ | [ |
5′-GCA GCT ATG TGG GGG ACG TCC AGC TGC-FAM-3′ 5′-TGG ATA CGG CCG GGT AGA TA-3′ | [ | ||||
| 2 | PCA3- Protein | Prostate cancer | Prognosis | 5′-AGUUUUUGCGUGUGCCCUUUUUGUCCCC-3′ | [ |
| PSA | Prostate cancer | Cleave semenogelins in the seminal coagulum | 5′-SH-(CH2)6-TTTTTTTTTTATTAAAGCTCGCCATCAAATAGCTGC-3′ 5′-SH-(CH2)6-TTTTTTTTTTGCAGCTATTT-Cy5-3′ AATTAAAGCTCGCCATCAAATAGCTTT GAGCGGGGTTGCTGGGATGATAAGGCCCCTTTGATGTCTG | [ | |
| 5′-GAGCGGGGTTGCTGGGATGATAAGGCCCCTTTGATGTCTG-3′ | [ | ||||
| 5′ -NH2-(CH2)6-TTT TTA ATT AAA GCT CGC CAT CAA ATA GCT TT-3′ | [ | ||||
| 5′-CCGUCAGGUCACGGCAGCGAAGCUCUAGGCGCGGCCAGUUGC-3 | [ | ||||
| 5′-HS-(CH2)6-ATT AAA GCT CGC CAT CAA ATA GC-3′ | [ | ||||
| 3 | MUC1 | Colon, breast, ovarian, lung, and pancreatic cancer | Protect cells from infection | 5′-NH2-GCAGTTGATCCTTTGGATACCCTGG- 3′ | [ |
| 4 | CEA | Colorectal cancer, esophageal cancer, gastric carcinoma, pancreatic carcinoma | Cancer diagnosis and treatment | 5′-Texas Red -ATACCAGCT TATTCAATT-3′, random ssDNA 5′-TCATTACATGTTTCCT TACTTC CAG-3′ | [ |
| SH-ATACCAGCTTATTCAATT | [ | ||||
| 5′-ATACCAGCTTATTCAATT-3′ | [ | ||||
| 5 | EpCAM | Colorectal, breast, gallbladder, pancreatic, liver cancer | Cancer diagnosis, prognosis, and therapy | 5′-/5carboxy1/-CAC TAC AGA GGT TGC GTC TGT CCC ACG TTG TCA TGG GGG GTT GGC CTG-3′ | [ |
| 6 | EGFR | Gastric, breast, ovarian, and colorectal cancers | Promotes cell division and proliferation | 5′-TAC CAG TGC GAT GCT CAG TGC CGT TTC TTC TCT TTC GCT TTT TTT GCT TTT GAG CAT GCT GAC GCA TTC GGT TGA C-3′ | [ |
| 7 | IL-6 | Lung cancer | Cytokine biomarker regulates immune responses | 5′-NH2- GGT GGC AGG AGG ACT ATT TAT TTG CTT TTC T -3′ | [ |
| Lung and breast cancer | Radiation injury biomarkers | 5′ -SHC6- TTTTT GGGGG AAAAA CTTCCAACGCTCGTATTGTCAGTCTTTAGT-3′ | [ | ||
| 8 | HER2 | Breast, gastric cancer | Downregulation of HER2 can induce apoptosis by altering cell proliferation and downstream signaling pathways | 5′-GCAGCGGTGTGGGG-3′ | [ |
| 5′-NH2-(CH2)6-GGG CCG TCG AAC ACG AGC ATG GTG CGT GGA CCT AGG ATG ACC TGA GTA CTG TCC-3′ | [ | ||||
| 5′-biotin-ACGACCCGATAAGTGCATTAGCACGTCCGAGAAAGGCCAGACGGGTCACACAGAGTTA-3′ | [ | ||||
| 5′-SH-(CH2)6-ATTAAGAACCATCA CTCTTCCAAATGGATATACGACTGGG-3′ | [ | ||||
| 5′ -TCT AAA AGG ATT CTT CCC AAG GGG ATC CAA TTC AAA CAG 6 S–S-3′ | [ | ||||
| [ThiC6]AACCGCCCAAATCCCTAAGAGTCTGCACTTGTCATTTTGTATATGTATTTGGTTTTTGGCTCTCACAGACACACTACACACGCA | [ | ||||
| 9 | HE4 | Ovarian cancer | Early detection | 5′-FAM-AGC AGC ACA GAG GTC AGA TG-3′, reverse primer 5′-biotin-TTC ACG GTA GCA CGC ATA GG-3′, 5′-FAM-AGC AGC ACA GAG GTC AGA TG (N)25 CCT ATG CGT GCT ACC GTG AA-3′ | [ |
| 10 | CA125 | Ovarian cancer | Early diagnosis | 5′- AAAAAACTCACTATAGGGAGACAAGAATAAACGCTC AA-3′ | [ |
| 11 | CRP | Cancer | Diagnose inflammatory reactions in cancer | 5′ -CGAAGGGGATTCGAGGGGTGATTGCGTGCTCCATTTGGTGTTTTTTTTTTTT-(CH2)6-NH2-3′ 5′-CGAAGGGGATTCGAGGGGTGATTGCGTGCTCCATTTGGTGTTTTTTTTTTTT-(CH2)6-SH-3′ | [ |
| 12 | AFP | Hepatocellular, prostate, and ovarian cancer | 5′-GGCAGGAAGACAAACAAGCTTGGCGGCGGGAAGGTGTTTAAATTCCCG GGTCTGCGTGGTCTGTGGTGCTGT-3′ | [ | |
| 5′-HS-(CH2)6- GTG-ACG-CTC-CTA-ACG-CTG-ACT-CAG-GTG-CAGTTC-TCG-ACT-CGG-TCT-TGA-TGT-GGG-TCC-TGTCCG-TCC-GAA-CCA-ATC-3′ | [ | ||||
| 13 | CTCs | Hepatocellular cancer, | Used to evaluate cancer metastasis | 5′-dithiol-TTTTTTTTTTACAGCATCCCCATGTGAACAATCGCATTGTGATTGTTACGGTTTCCGCCTCATGGACGTGCTG-3′ ZY5C aptamer 5′-SHC6TTTTTTTTTTCACGCATAGCCTTTGCTCCTCGTCTGGAACGTCGCAGCTTTAGTTCTGGGCCTATGCGTG-3′ | [ |
| Ovarian cancer | 5′ -GCAGGAAGACAAACA-N40-GGTCTGTGGTGCTGT3′ | [ | |||
| 5′-SHCACTACAGAGGTTGCGTCTGTCCCACGTTGTC ATGGGGGGTTGGCCTG | [ | ||||
| 14 | Tg | Thyroid cancer | Diagnosis and postoperative monitoring | Primer sequences (forward 5′ -CCTAACCGATATCACACTCAC-3′, reverse 5′ -GATACTCCAATGACGACCAAC-3′) and the random ssDNA library (82 nt, 5′ -FAM-CCTAACCGATATCACACTCAC-N40- GTTGGTCGTCATTGGAGTATC-3′) | [ |
| 15 | NCL | Prostate cancer | Regulation of several mechanisms related to nucleic acid metabolism and tumor prognosis | 5′—FAMGTTGGGGTGGTGGTGGTTGTGGTGGTGGTGGCCAAC-Dabcyl -3′ | [ |
| 5′-GGTGGTGGTGGTTGTGGTGGTGGTGG-Rox-3ˊ | [ | ||||
| 16 | AGR2 | Pancreatic, breast, ovarian, prostate, and colorectal cancer | Early diagnosis | 5′-CG3TG3AGT2GTG9TG3AG3T2-3′ | [ |
| 17 | STIP1 | Ovarian cancer | Prognosis | 5′-ATCCAGAGTGACGCAGCA CGGCACTCACTCTTTGTTAAGTGGTCTGCTTCTTAA CCTTCATCGACACGGTGGCTTA-3′ | [ |
| 18 | lncPCA3 | Prostate cancer | Predict prostatic biopsies | 5′- AGUUUUUGCGUGUGCCCUUUUUGUCCCC-3′SH | [ |
| 19 | PDGF-BB | Breast, pancreatic, prostate, ovarian, and liver | Play a potent role in the growth and metastasis | 5′-C6-CAG GCT ACG GCA CGT AGA GCA TCA CCA TGA TCC TG-3′ | [ |
| 20 | KIT | Cancer | 5′-GAG GCA TAC CAG CTT ATT CAA GGG GCC GGG GCA AGG GGG GGG TAC CGT GGT AGG ACA TAG TAA GTG CAA TCT GCG AA-3′ | [ | |
| 21 | PTK7 | Breast, lung, colon, and gastric cancer | plays important role in cell regulation, ion transport, and cancer development | 5′-H2N-ATC TTA CTG CTG CGC CGC CGG GAA AAT ACT GTA CGG TTA GAT TTT TTT TTT-3′ | [ |
| 22 | Thy-1 | Pancreatic ductal adenocarcinoma | Facilitate the attachment of tumor cells to endothelial cells and promote tumor metastasis | 5′-CAGGGGACGCACCAAGG-TTGCCCACAGAWCYGTGGAAGCCGAACCGCGTGCWAGXCGYG-CCATGACCCGCGTGCTG-3′ 5′-CAGGGGACGCACCAAGG-TTGCCCACCYCCCYGTGCGGGCCACAGAGCAGCAGTGXCGYG- CCATGACCCGCGTGCTG-3′ 5′-CAGGGGACGCACCAAGG-TTGCCCACCGWACYGTGCAGGXCGAACTACAGGCACGXCGYG- CCATGACCCGCGTGCTG-3′ | [ |
Fig. 3a Synthesis method for aptamer and detection through electrochemical method, b comparison of aptamers and antibodies as biorecognition element
Fig. 4a Structure of MXene. b Synthesis of MXene. c Dimensional-based classification. d Properties of MXene
Fig. 5Steps associated with the production of the MAX phase: a ball milling, b passivation by oxygen, c high-temperature synthesis, and d acid washing to remove interferents
Fig. 6Synthesis method of MXene. a Top-down synthesis method, b wet chemical etching method, c salt-template synthesis by the bottom-up method, d safety measures and general instructions for laboratory
Fig. 7a Schematic representation of the preparation of 3D macroporous PANI@M-Ti3C2T frameworks with PS spheres as a template, inset showing SEM images of the formed 3D PANI@M–Ti3C2T film. Copyright from Ref. [163]. b Synthesis of Ti3C2Tx via two different routes with or without sonication, inset showing AFM images of the synthesized Ti3C2Tx flakes. Copyright from Ref. [164]. c XRD patterns of Ti3AlC2 powder and Ti3C2Tx MXene powders synthesized with 5, 10, and 30%wt HF and in situ HF by using NH4-Ti3C2Tx routes. Copyright from Ref. [165]. d The SEM image of MXenes at 500 nm. Copyright from Ref. [166]. e HR-TEM images of Ti3C2Tx@FePcQDs hybrid structure. Copyright from Ref. [167]. f FTIR spectrum, g XPS spectra of various samples. Copyright from Ref. [141]. h Raman spectra of bulk MXene and MXene quantum dots. i UV–Vis absorption spectrum of MXene QDs; the inset showing the value of the bandgap fitted. j Excitation and emission spectra of MXene QDs. Copyright from Ref. [140]
Fig. 8a Local density of states for Mo2HfC2O2 on the zigzag edge. The edge states connecting the bulk valence and conduction bands form a single Dirac cone at the M point. Copyright from Ref. [188]. b The density of states of Cr2CF2 (left panel) and Cr2CFCl (right panel) supported on the SiC(0001) substrate. Copyright from Ref. [192]. c Band structure and Fermi surface. Band structure and (III, IV) corresponding FS of (I, III) Bernal and (II, IV) SH Ti3C2(OH)2. FS1 (magenta) and FS2 (orange) partially degenerate. FS3 (green) and FS4 (violet) are partially degenerated. Copyright from Ref. [200]. d Work functions of MXenes with various terminations. For comparison, the work functions of Sc and Pt are also shown by dashed lines. Copyright from Ref. [201]. e Band structure for Cr2C MXene. The weights of the Cr d are represented in black and C p orbitals are represented in green. Copyright from Ref. [202]
MXene-based electrochemical aptasensors for cancer diagnosis (sensitivity and detection limit)
| S. no. | Material | Biomarker | Sample | Technique | Linear range | LOD | References |
|---|---|---|---|---|---|---|---|
| 1 | MXenes-BPQDs@Ru(dcbpy)32+-PEIAbCD63 | Exosomes, CD63 | CV | 1.1 × 102 to 1.1 × 107 particles µL−1 | 37.0 particles µL−1 | [ | |
| 2 | 0D/2D Ti3C2Tx@FePcQD nanohybrid | miRNA-155 | Serum | EIS | 0.01 fM to 10 pM | 4.3 aM | [ |
| 3 | cDNA-Fc/MXene/Apt/Au/GCE aptasensor | Mucin 1 | Serum | SWV | 1.0 to 10 µM | 0.33 pM | [ |
| 4 | MPA-CdS:Eu NC | Exosomes, CD63 | Serum | EIS, ECL | 3.4 × 105 to 1.7 × 108 | 7.41 × 104 particles mL−1 | [ |
| 5 | Ti3C2 MXene (MXene) | Exosomes, CD63 | Cancer cells and Serum | CV, EIS | 5 × 102 to 5 × 105 particles µL−1 | 229 particles µL−1 | [ |
| 6 | PPy@Ti3C2Tx/PMo12 | Osteopontin | Serum | EIS | – | 0.98 fg mL−1 | [ |
| 7 | AuNPs/Ti3C2 MXene | miRNA-155 | EIS, CV | 1.0 fM to 10 nM | 0.35 fg | [ | |
| 8 | MXenes-Apt2/exosomes/Apt1/PNIPAM-AuNPs/GCE | Exosomes, CD63 | Serum | ECL | 5.0 × 102 to 5.0 × 106 particles µL−1 | 125 particles µL−1 | [ |
| 9 | MXene-MoS2-Thi-AuNPs/GCE | miRNA-21 | Serum | CV, EIS, SWV | – | 26 fM | [ |
| 10 | CoFe2O4@Ag-HB5 cytosensor | HER2 positive cells | Blood sample | CV, EIS | 102 to 106 cells mL−1 | 47 cells mL−1 | [ |
| 11 | eCoCu-ZIF@CD-based cytosensor | PTK7B16-F10 cells | EIS, CV | 1.0 × 102 to 1.0 × 105 cells mL−1 | 33 cells mL−1 | [ |
Fig. 9a Representation of the laser patterning of paper coated with MXene to form an interdigitated electrode for MSCs devices. Copyright from Ref. [213]. b Schematic illustrating the fabrication process of the all-Ti3C2Tx MXene MSC. Copyright from Ref. [215]. c The electronic band-gap for various MXenes sheets. Copyright from Ref. [214]. d (I) CV curves of different modified electrodes. Copyright from Ref. [166], (II) DPV responses to different concentrations (2 to 500 pg mL−1) of CEA antigens. Copyright from Ref. [216], (III) EIS Nyquist plots of the miRNA-155 detection in 5.0 mM [Fe(CN)6]3−/4− containing 0.01 M PBS. Copyright from Ref. [167]. (IV) The corresponding variations of the Rct values with different concentrations (0.1, 0.5, 1, and 2 mgmL−1) for detecting miRNA-155 detection procedures (n = 3). Copyright from Ref. [167]
Fig. 10Futuristic application of MXene toward personalized healthcare management